A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab (pembro), lenvatinib, and chemotherapy in patients (pts) with metastatic non-small cell lung cancer (NSCLC) harbouring a targetable mutation who experienced disease...

Autor:	Chan, Hoi Wai, Tse, Chris Chun Long, Li, Yu-Chung, Leung, Roland Ching-Yu, Wong, Jeffrey Sum Lung, Kwok, Gin Wai, Li, Hoi Lam, Tsang, Wing Yan Josephine, Li, Cho Wing, Lo, Jenny WY, Tang, Vikki, Hui, Rina, Yau, Thomas, Ho, James CM, Chiu, Joanne W
Zdroj:	Journal of Clinical Oncology; 2024 Supplement, Vol. 42, p198-198, 24p
Databáze:	Supplemental Index
Externí odkaz:	Zobrazit plný text záznamu